Novartis nears deal to acquire Avidity Biosciences for over $70 per share, Bloomberg News reports
PositiveFinancial Markets

Novartis is reportedly close to finalizing a deal to acquire Avidity Biosciences for more than $70 per share, according to Bloomberg News. This acquisition could significantly enhance Novartis's portfolio in the biotechnology sector, allowing them to leverage Avidity's innovative technologies and research capabilities. Such a move not only reflects Novartis's commitment to expanding its reach in the market but also highlights the growing interest in gene therapies and RNA-targeted treatments.
— Curated by the World Pulse Now AI Editorial System










